Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06434636
Other study ID # 2024/88
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 2024
Est. completion date June 2025

Study information

Verified date May 2024
Source TC Erciyes University
Contact Talha ERSOY, MD
Phone +905316682730
Email drdrtalhaersoy@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

By using tranexamic acid, an antifibrinolytic drug, the aim is to prevent the restriction of the field of view of the surgical field due to bleeding in middle ear microscopic and endoscopic surgery operations in which controlled hypotension is applied, and therefore the prolongation of the surgical time, and to increase surgeon satisfaction.


Description:

After obtaining approval from our university and the Turkish Ministry of Health's pharmaceutical and medical device agency and written consent from the patients, 100 patients who underwent middle ear surgery using controlled hypotension under general anesthesia will be included in the study. The study will be conducted in a randomized controlled, double-blind manner. Patients between the ages of 18-65 and with American Society of Anesthesiologists (ASA) Scores I and II will be included in the study. Patients will be divided into two groups: Intervention (M) and Control (C). Just before the operation begins, 10 mg/kg tranexamic acid (TXA) will be administered to the intervention group in 100 mL of 0.9% physiological saline (SF) solution in 15 minutes. 100 mL of 0.9% SF solution will be sent to the control group in 15 minutes. At the end of the operation, the operator's quality of vision of the surgical field will be recorded by questioning the surgeon's satisfaction with the Boezaart Score and the Surgeon Satisfaction Score.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date June 2025
Est. primary completion date May 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Individuals between the ages of 18-65 - Individuals with ASA I (no additional disease) or ASA II (mild systemic disease) - Those who do not have a disease such as thrombophilia or bleeding diathesis will be included in the study Exclusion Criteria: - Patients with ASA III (those with uncontrolled chronic disease) or above - Patients with cardiovascular disease, congestive heart failure, coronary artery disease, cerebrovascular insufficiency, renal or hepatic failure - Patients with thrombophilia, bleeding diathesis, coagulation defects - Pregnant patients - Those with a history of any allergic reaction to tranexamic acid and its derivatives will be excluded from the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Transamine 10% IV/IM Solution for Injection
10 mg/kg tranexamic acid (Transamine 10% IV/IM Injectable Solution) will be placed into 100 cc physiological saline through the appropriate vascular access and injected within 15 minutes.
%0.9 Saline
100 cc %0.9 Normal Saline will be injected through the appropriate vascular access within 15 minutes

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
TC Erciyes University

Outcome

Type Measure Description Time frame Safety issue
Primary Boezaart et al grading scale At the end of a surgery, the surgical field was graded in terms of bleeding by the surgeon using the scale used by Boezaart et al in 1995;
0 : No bleeding (cadaveric conditions).
: Slight bleeding: no suctioning required.
: Slight bleeding: occasional suctioning required.
: Slight bleeding: frequent suctioning required. Bleeding threatens surgical field a few seconds after suction is removed.
: Moderate bleeding: frequent suctioning required and bleeding threatens surgical field directly after suction is removed.
: Severe bleeding: constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible.
2-3 hours
Primary Surgeon Satisfaction Score At the and of surgery , surgeon's satisfaction with surgical field quality was also graded in a 5-item Likert scale, where 1 = poor and 5 = excellent 2-3 hours
See also
  Status Clinical Trial Phase
Completed NCT04776967 - Effect of Total Compression Time and Rate (Slope) on Incidence of Symptomatic ETD and MEB: A Phase II Prospective Study. N/A
Recruiting NCT04804098 - Effect of Rate (Slope) of Compression on the Incidence of Symptomatic ETD and MEB: a Phase III Prospective Study. N/A
Completed NCT01925729 - TransMEM Gas Exchange -- Project 1, Aim 2 Phase 1
Withdrawn NCT05085379 - Optical Coherence Tomography of the Middle Ear Using Ossiview
Recruiting NCT03297736 - Improved Otologic Implants on Demand Intraoperatively With 3D CAD/CAM Autografts N/A
Recruiting NCT05055115 - Ph.D.-Project: Eustachian Tube Dysfunction: Causes, Diagnosis, Treatment, and Prognosis N/A
Completed NCT05813119 - Efficacy of Digital Otoscope and Otoendoscope for Diagnosis of Middle Ear Pathology